Studies Reignite Debate over Avastin (Bevacizumab) in Breast Cancer - in Oncology/Hematology, Breast Cancer from MedPage Today

Action Points

---

• These two studies found a benefit in the surrogate endpoint of complete pathologic response with the addition of bevacizumab in neoadjuvant treatment for HER2-negative breast cancer.



• Note that pathologic complete response was defined differently in the two studies -- in the breast and nodes in one and only in the breast in the other; applying the more stringent breast-plus-nodes criterion in the second study eliminated the statistical significance.